Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

Matteo Santoni, Francesco Massari, Vincenzo Di Nunno, Alessandro Conti, Alessia Cimadamore, Marina Scarpelli, Rodolfo Montironi, Liang Cheng, Nicola Battelli, Antonio Lopez-Beltran

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.

Original languageEnglish (US)
Article number212528
JournalDrugs in Context
Volume7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Vascular Endothelial Growth Factor Receptor
Tumor Microenvironment
Tumor Biomarkers
Protein-Tyrosine Kinases
Immunosuppression
Neoplasms
Clinical Trials
Ligands
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Immunocheckpoint inhibitors
  • Immunotherapy
  • PD-1
  • Renal cell carcinoma
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Santoni, M., Massari, F., Di Nunno, V., Conti, A., Cimadamore, A., Scarpelli, M., ... Lopez-Beltran, A. (2018). Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context, 7, [212528]. https://doi.org/10.7573/dic.212528

Immunotherapy in renal cell carcinoma : latest evidence and clinical implications. / Santoni, Matteo; Massari, Francesco; Di Nunno, Vincenzo; Conti, Alessandro; Cimadamore, Alessia; Scarpelli, Marina; Montironi, Rodolfo; Cheng, Liang; Battelli, Nicola; Lopez-Beltran, Antonio.

In: Drugs in Context, Vol. 7, 212528, 01.01.2018.

Research output: Contribution to journalReview article

Santoni, M, Massari, F, Di Nunno, V, Conti, A, Cimadamore, A, Scarpelli, M, Montironi, R, Cheng, L, Battelli, N & Lopez-Beltran, A 2018, 'Immunotherapy in renal cell carcinoma: latest evidence and clinical implications', Drugs in Context, vol. 7, 212528. https://doi.org/10.7573/dic.212528
Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context. 2018 Jan 1;7. 212528. https://doi.org/10.7573/dic.212528
Santoni, Matteo ; Massari, Francesco ; Di Nunno, Vincenzo ; Conti, Alessandro ; Cimadamore, Alessia ; Scarpelli, Marina ; Montironi, Rodolfo ; Cheng, Liang ; Battelli, Nicola ; Lopez-Beltran, Antonio. / Immunotherapy in renal cell carcinoma : latest evidence and clinical implications. In: Drugs in Context. 2018 ; Vol. 7.
@article{dc14f14b776b4bacb9cf6ed7a8416eee,
title = "Immunotherapy in renal cell carcinoma: latest evidence and clinical implications",
abstract = "Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.",
keywords = "Immunocheckpoint inhibitors, Immunotherapy, PD-1, Renal cell carcinoma, Tyrosine kinase inhibitors",
author = "Matteo Santoni and Francesco Massari and {Di Nunno}, Vincenzo and Alessandro Conti and Alessia Cimadamore and Marina Scarpelli and Rodolfo Montironi and Liang Cheng and Nicola Battelli and Antonio Lopez-Beltran",
year = "2018",
month = "1",
day = "1",
doi = "10.7573/dic.212528",
language = "English (US)",
volume = "7",
journal = "Drugs in Context",
issn = "1745-1981",
publisher = "JUST Medical Media Limited",

}

TY - JOUR

T1 - Immunotherapy in renal cell carcinoma

T2 - latest evidence and clinical implications

AU - Santoni, Matteo

AU - Massari, Francesco

AU - Di Nunno, Vincenzo

AU - Conti, Alessandro

AU - Cimadamore, Alessia

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Battelli, Nicola

AU - Lopez-Beltran, Antonio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.

AB - Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.

KW - Immunocheckpoint inhibitors

KW - Immunotherapy

KW - PD-1

KW - Renal cell carcinoma

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85052761779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052761779&partnerID=8YFLogxK

U2 - 10.7573/dic.212528

DO - 10.7573/dic.212528

M3 - Review article

AN - SCOPUS:85052761779

VL - 7

JO - Drugs in Context

JF - Drugs in Context

SN - 1745-1981

M1 - 212528

ER -